Personalis, Inc. - PSNL STOCK NEWS

Personalis, Inc. (NASDAQ: PSNL) has announced that it will release its first quarter 2023 financial results on May 3, 2023. A conference call and webcast will follow at 2:00 p.m. Pacific Time to discuss the financial outcomes and company milestones. Interested parties can access the call via phone or through the company's website. Personalis specializes in advanced genomics aimed at improving cancer management through personalized testing and highly sensitive assays.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has announced its participation in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference. This event is scheduled for Wednesday, April 19 at 3:00 p.m. Eastern Time. The company focuses on transforming cancer management through personalized testing, offering assays that combine tumor profiling with proprietary algorithms for advanced patient insights. Their products aim to detect minimal residual disease and optimize targeted therapies based on comprehensive genomic profiling. Personalis is based in Fremont, California.

Personalis has partnered with Cancer Research UK's Cancer Research Horizons, University College London, and the Francis Crick Institute to utilize its NeXT Personal liquid biopsy assay in the TRACERx study, aiming to improve early detection of lung cancer recurrence after surgery. The NeXT Personal assay offers high sensitivity in identifying circulating tumor DNA (ctDNA) in blood samples, enabling earlier detection of residual disease. This collaboration seeks to enhance patient care by tracking minimal residual disease (MRD) and providing insights for more informed treatment decisions in lung cancer patients.

Personalis (Nasdaq: PSNL) has presented new research at the AACR Annual Meeting 2023 highlighting its advanced cancer monitoring technologies. Key findings demonstrate the effectiveness of NeXT Personal® in detecting circulating tumor DNA (ctDNA), offering the potential for earlier therapy response prediction compared to imaging methods.

Collaborating with University Medical Center Hamburg-Eppendorf, the company aims to support the routine clinical use of minimal residual disease (MRD) detection in immunotherapy. Initial results indicate enhanced survival rates linked to ctDNA clearance in melanoma patients, showcasing the platform's high sensitivity and accuracy.

Personalis, Inc. (Nasdaq: PSNL) announced an ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement using Personalis' NeXT Personal® assay. This partnership aims to enhance the detection of circulating tumor DNA (ctDNA) and clinically relevant mutations to guide cancer therapy. The CALLA trial will focus on locally advanced cervical cancer, assessing the roles of ctDNA and HPV detection in plasma. Personalis emphasizes the assay's high sensitivity and specificity, crucial for early and personalized patient interventions.

Personalis (NASDAQ: PSNL) has announced a major leadership change aimed at progressing its strategic objectives in cancer management. Christopher Hall is appointed as the new CEO, effective immediately, alongside Aaron Tachibana promoted to COO, and Dr. Richard Chen to EVP, R&D. This leadership shift follows Hall's previous role as President since December 2022. The company's focus will be on minimal residual disease (MRD) testing and supporting personalized cancer therapies. As they work to reduce cash burn and enhance margins, these appointments are expected to bolster Personalis's position in advanced genomics.

Personalis, Inc. (Nasdaq: PSNL) reported a fourth quarter revenue of $16.7 million and a full year revenue of $65.0 million for 2022. The company experienced a net loss of $31.1 million in Q4 and $113.3 million for the year. Notably, revenue from pharma tests and enterprise customers reached $15.8 million in Q4. The firm has announced partnerships with Moderna and ongoing collaborations for clinical trials to enhance cancer treatment monitoring. For Q1 2023, Personalis expects approximately $17.5 million in revenue with a full-year forecast between $68 million and $72 million.

Personalis, Inc. (NASDAQ: PSNL) announced it will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call and webcast will be held on the same day at 2:00 p.m. PT to discuss these results along with recent highlights. Interested participants can register in advance to access the live call. The company focuses on advanced cancer genomics, providing insights on approximately 20,000 human genes through its Personalis NeXT Platform. The laboratory is certified and accredited for its clinical accuracy and efficiency. More updates will be available after the conclusion of the call.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will participate in two upcoming investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2023, at The Cliff Lodge in Snowbird, UT. The second is the 43rd Annual Cowen Healthcare Conference on March 7, 2023, at 10:30 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA. Personalis is known for its NeXT Platform, which offers comprehensive insights into the human genome, aiding in precision cancer therapies. The company's laboratory is recognized for its clinical accuracy and quality.